{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:51:10Z","timestamp":1792011070700,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00280-007-0567-8","type":"journal-article","created":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T08:49:35Z","timestamp":1188290975000},"page":"875-882","source":"Crossref","is-referenced-by-count":27,"title":["Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Izuru","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kasuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Kanazumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"567_CR1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM199202133260706","volume":"326","author":"AL Warshaw","year":"1992","unstructured":"Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455\u2013464","journal-title":"N Engl J Med"},{"key":"567_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"9","key":"567_CR3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.cgt.7700830","volume":"12","author":"H Kasuya","year":"2005","unstructured":"Kasuya H, Takeda S, Nomoto S, Nakao A (2005) The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12(9):725\u2013736","journal-title":"Cancer Gene Ther"},{"key":"567_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/B:NEON.0000003657.95085.56","volume":"65","author":"IM Germano","year":"2003","unstructured":"Germano IM, Fable J, Gultekin SH, Silvers A (2003) Adenovirus\/herpes simplex-thymidine kinase\/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neuro oncol 65:279\u2013289","journal-title":"J Neuro oncol"},{"key":"567_CR5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2004.08.002","volume":"10","author":"A Immonen","year":"2004","unstructured":"Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomized, controlled study. Mol Ther 10:967\u2013972","journal-title":"Mol Ther"},{"key":"567_CR6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ijrobp.2003.09.083","volume":"58","author":"BS Teh","year":"2004","unstructured":"Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, et al (2004) Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer- interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58:1520\u20131529","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"567_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/10430340360535788","volume":"14","author":"H Kubo","year":"2003","unstructured":"Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, et al (2003) Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14:227\u2013241","journal-title":"Hum Gene Ther"},{"key":"567_CR8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.gt.3301398","volume":"8","author":"S Mulvihill","year":"2001","unstructured":"Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, et al (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinoma of the pancreas: a phase I trial. Gene Ther 8:308\u2013315","journal-title":"Gene Ther"},{"key":"567_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdh225","volume":"15","author":"A Nakao","year":"2004","unstructured":"Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, et al (2004) Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 15:987\u2013991","journal-title":"Ann Oncol"},{"key":"567_CR10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/BF02725338","volume":"7","author":"JP Lamont","year":"2000","unstructured":"Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM (2000) A prospective phase II trial of ONXY-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 7:588\u2013592","journal-title":"Ann Surg Oncol"},{"key":"567_CR11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","volume":"8","author":"J Neumunaitis","year":"2001","unstructured":"Neumunaitis J, Cunningham C, Buchnan A, Edelman G, Maples P, Netto G, et al (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8:746\u2013759","journal-title":"Gene Ther"},{"key":"567_CR12","first-page":"4024","volume":"48","author":"V Heinemann","year":"1988","unstructured":"Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2\u2019,2\u2019-difluorodeoxycytidine and 1-\u03b2-d\u2013arabinofuranosylcytosine. Cancer Res 48:4024\u20134031","journal-title":"Cancer Res"},{"key":"567_CR13","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Plunkett W (1991) Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110\u20136117","journal-title":"Cancer Res"},{"key":"567_CR14","first-page":"567","volume":"38","author":"V Heinemann","year":"1990","unstructured":"Heinemann V, Xu Y, Chubb S, Sen A, Hertel LW, Grindey GB, et al (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2019, 2\u2019-difluorodeoxycytidine. Mol Pharmacol 38:567\u2013572","journal-title":"Mol Pharmacol"},{"key":"567_CR15","doi-asserted-by":"crossref","first-page":"4215s","DOI":"10.1158\/1078-0432.CCR-040006","volume":"10","author":"R Rosell","year":"2004","unstructured":"Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, et al (2004) Gene expression as a predictive marker of outcome in stage ((B-IIIA-IIIB non- small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10:4215s\u20134219s","journal-title":"Clin Cancer Res"},{"key":"567_CR16","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","volume":"64","author":"JD Davidson","year":"2004","unstructured":"Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64:3761\u20133766","journal-title":"Cancer Res"},{"key":"567_CR17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-03-0156","volume":"10","author":"R Rosell","year":"2004","unstructured":"Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318\u20131325","journal-title":"Clin Cancer Res"},{"key":"567_CR18","first-page":"4204","volume":"59","author":"YG Goan","year":"1999","unstructured":"Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59:4204\u20134207","journal-title":"Cancer Res"},{"key":"567_CR19","first-page":"2527","volume":"7","author":"CP Jung","year":"2001","unstructured":"Jung CP, Motwani MV, Schwartz GK (2001) Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7:2527\u20132536","journal-title":"Clin Cancer Res"},{"key":"567_CR20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/sj.onc.1207272","volume":"23","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539\u20131548","journal-title":"Oncogene"},{"key":"567_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.surg.2004.04.029","volume":"136","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2004) Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer. Surgery 136:261\u2013269","journal-title":"Surgery"},{"key":"567_CR22","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.93.21.11313","volume":"93","author":"SS Andreansky","year":"1996","unstructured":"Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, et al (1996) The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93:11313\u201311318","journal-title":"Proc Natl Acad Sci USA"},{"key":"567_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.1997.8.5-533","volume":"8","author":"RB Pyles","year":"1997","unstructured":"Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM (1997) A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 8:533\u2013544","journal-title":"Hum Gene Ther"},{"key":"567_CR24","first-page":"3342","volume":"6","author":"G Coukos","year":"2004","unstructured":"Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL (2004) Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 6:3342\u20133353","journal-title":"Clin Cancer Res"},{"key":"567_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/(SICI)1096-9098(199911)72:3<136::AID-JSO5>3.0.CO;2-3","volume":"72","author":"H Kasuya","year":"1999","unstructured":"Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A (1999) Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 72:136\u2013141","journal-title":"J Surg Oncol"},{"key":"567_CR26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/1096-9098(200007)74:3<214::AID-JSO12>3.0.CO;2-Y","volume":"74","author":"H Kasuya","year":"2000","unstructured":"Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S, Nakao A (2000) Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. J Surg Oncol 74:214\u2013218","journal-title":"J Surg Oncol"},{"key":"567_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00000658-199609000-00008","volume":"224","author":"NM Carroll","year":"1996","unstructured":"Carroll NM, Chiocca EA, Takahashi K, Tanabe KK (1996) Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224:323\u2013330","journal-title":"Ann Surg"},{"key":"567_CR28","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-03-3431","volume":"64","author":"H Kasuya","year":"2004","unstructured":"Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, et al (2004) Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3\/MUC1 antigen. Cancer Res 64:2561\u20132567","journal-title":"Cancer Res"},{"key":"567_CR29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1096\/fasebj.14.2.301","volume":"14","author":"SS Yoon","year":"2000","unstructured":"Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK (2000) An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 14:301\u2013311","journal-title":"FASEB J"},{"key":"567_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0042-6822(88)90144-4","volume":"166","author":"DJ Goldstein","year":"1988","unstructured":"Goldstein DJ, Weller S (1988) Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41\u201351","journal-title":"Virology"},{"key":"567_CR31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2003.10.019","volume":"319","author":"PD Ogg","year":"2004","unstructured":"Ogg PD, McDonell PJ, Ryckman BJ, Knudson CM, Roller RJ (2004) The HSV-1 Us3 protein kinase is sufficient to block apotosis induced by overexpression of a variety of Bcl-2 family members. Virology 319:212\u2013224","journal-title":"Virology"},{"key":"567_CR32","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.1073\/pnas.0403160101","volume":"101","author":"L Benetti","year":"2004","unstructured":"Benetti L, Roizman B (2004) Herpes simplex virus protein kinase Us3 activates and functionally overlaps protein kinase A to block apotosis. Proc Natl Acad Sci USA 101:9411\u20139416","journal-title":"Proc Natl Acad Sci USA"},{"key":"567_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.onc.1200848","volume":"14","author":"DC Huang","year":"1997","unstructured":"Huang DC, Cory S, Strasser A (1997) Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14:405\u2013414","journal-title":"Oncogene"},{"key":"567_CR34","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/JVI.71.5.3620-3627.1997","volume":"71","author":"JG Teodoro","year":"1997","unstructured":"Teodoro JG, Branton PE (1997) Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. J Virol 71:3620\u20133627","journal-title":"J Virol"},{"key":"567_CR35","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/JVI.71.3.1739-1746.1997","volume":"71","author":"JG Teodoro","year":"1997","unstructured":"Teodoro JG, Branton PE (1997) Regulation of apoptosis by viral gene products. J Virol 71:1739\u20131746","journal-title":"J Virol"},{"key":"567_CR36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0959-437X(98)80066-X","volume":"8","author":"J Tschopp","year":"1998","unstructured":"Tschopp J, Thome M, Hofmann K, Meinl E (1998) The fight of viruses against apoptosis. Curr Opin Genet Dev 8:82\u201387","journal-title":"Curr Opin Genet Dev"},{"key":"567_CR37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.04265","volume":"6","author":"J Cinatl Jr","year":"2004","unstructured":"Cinatl J Jr, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, et al (2004) Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasis 6:725\u2013735","journal-title":"Neoplasis"},{"key":"567_CR38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1172\/JCI0210623","volume":"109","author":"H Nakamura","year":"2002","unstructured":"Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, et al (2002) Regulation of herpes simplex virus g1 34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 109:871\u2013882","journal-title":"J Clin Invest"},{"key":"567_CR39","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1128\/JVI.73.9.7556-7564.1999","volume":"73","author":"RY Chung","year":"1999","unstructured":"Chung RY, Saeki Y, Chioca EA (1999) \u03b2-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73:7556\u20137564","journal-title":"J Virol"},{"key":"567_CR40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.20005","volume":"85","author":"O Teshigahara","year":"2004","unstructured":"Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, et al (2004) Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF10. J Surg Oncol 85:42\u201347","journal-title":"J Surg Oncol"},{"key":"567_CR41","first-page":"961","volume":"50","author":"H Kimata","year":"2003","unstructured":"Kimata H, Takakuwa H, Goshima F, Teshigahara O, Nakao A, Kurata T, et al (2003) Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 50:961\u2013966","journal-title":"Hepatogastroenterology"},{"key":"567_CR42","doi-asserted-by":"crossref","first-page":"9829","DOI":"10.1073\/pnas.92.21.9829","volume":"92","author":"G Nilaver","year":"1995","unstructured":"Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, et al (1995) Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 92:9829\u20139833","journal-title":"Proc Natl Acad Sci USA"},{"key":"567_CR43","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-03-3431","volume":"64","author":"H Kasuya","year":"2004","unstructured":"Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, et al (2004) Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3\/MUC1 antigen. Cancer Res 64:2561\u20132567","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0567-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0567-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0567-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T04:57:55Z","timestamp":1587877075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0567-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,29]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["567"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0567-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,29]]}}}